Stay updated with breaking news from Bio Path. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Bio-Path (NASDAQ:BPTH – Get Rating) was downgraded by Zacks Investment Research from a “hold” rating to a “sell” rating in a report released on Friday, Zacks.com reports. According to Zacks, “BIO-PATH is developing leading-edge, patented, liposomal drug delivery systems, with two clinical cancer drug candidates ready for the clinic and a third siRNA cancer drug […]
BELLAIRE, Texas (AP) _ Bio-Path Holdings Inc. (BPTH) on Monday reported a loss of $3.4...
StockNews.com began coverage on shares of Bio-Path (NASDAQ:BPTH – Get Rating) in a research note issued to investors on Friday. The firm set a “sell” rating on the stock. Separately, Zacks Investment Research lowered Bio-Path from a “hold” rating to a “sell” rating in a research note on Wednesday. NASDAQ:BPTH opened at $2.84 on Friday. […]
Equities research analysts expect Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) to report ($0.46) earnings per share for the current quarter, according to Zacks. Zero analysts have made estimates for Bio-Path’s earnings, with the highest EPS estimate coming in at ($0.39) and the lowest estimate coming in at ($0.52). Bio-Path reported earnings per share of […]
Brokerages expect Bio-Path Holdings, Inc. (NASDAQ:BPTH – Get Rating) to announce earnings per share (EPS) of ($0.46) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Bio-Path’s earnings, with estimates ranging from ($0.52) to ($0.39). Bio-Path posted earnings of ($0.43) per share in the same quarter last year, which […]